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Description
Field of the invention
[0001] The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its ana-
logues/ derivatives as well as their acceptable salts, for the production of a medicament for the treatment of preterm
labor and/or premature birth.
Background of the invention
[0002] Premature birth (also known as premature birth) is a big problem of our days. It is defined as birth ocurring
earlier than 37 completed weeks of gestation - in comparison to 40 weeks of gestation of normal gestation. In the U.S.
only 12 percent of babies are born prematurely each year - corresponding to more than 490,000 cases in the year 2003.
The main reason for these premature births is the ocurrence of preterm labor; stopping premature labor is crucial for
preventing preterm birth but so far no effective treatment is known.
[0003] Therefore, the objective of the present invention was to provide a new form of treatment for premature birth/
preterm labor.
[0004] It has now surprisingly been found that administration of TTX is highly effective in preventing uterus contractions,
which is a very promising result with respect to the treatment of premature birth and/or premature birth.
[0005] Thus, the present invention relates to the use of sodium channel blockers such as TTX or STX, its analogues/
derivatives, optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in
the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable mixing ratio; in neutral
form, in the form of an acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate,
especially a hydrate for the production of a medicament for the treatment of preterm labor and/or premature birth.
[0006] The term "premature birth" as mentioned in the present invention refers to a birth occurring earlier than 37
completed weeks of gestation. Risk factors for premature birth include multiple pregnancies (twins, triplets, etc.), uterine
or cervical abnormalities, certain chronic disease such as high blood pressure, kidney disease and diabetes, infections
of the cervix, uterus or urinary tract, substance abuse of tobacco, alcohol and other drugs, age under 18 or over 35
years, inadequate nutrition during pregnancy, antepartum hemorrhage, pre- eclampsia or stress. As in a normal birth, in
a premature birth the inner diameter of the cervix is greater than 3 cm and the length of the cervix is reduced by about 50%.
[0007] The term "preterm labor" according to the present invention refers to uterine contractions before completion of
37 weeks of gestation. Optionally, these contractions may lead to premature birth. A possible definition of preterm labor
is via the frequency of uterus contractions. Preferably, preterm labor, as referred to in the present invention, is defined
by a number of uterus contractions of ≥4 per hour; more preferably ≥8 contractions per hour; most preferably, the number
of uterus contractions is ≥12 per hour.
[0008] The term "analogues" as used in this application is defined here as meaning a chemical compound that is a
derivative of a compound which has similar biochemical activity to that compound. For example, "Analogues" of TTX
bind to the same site on the alpha subunit of sodium channels as does TTX.
[0009] The term "derivatives" as used in this application is defined here as meaning a chemical compound having
undergone a chemical derivation such as substitution or addition of a further chemical group to change (for pharmaceutical
use) any of its physico-chemical properties, such as solubility or bioavailability. Derivatives include so- called prodrugs,
e.g. ester and ether derivatives of an active compound that yield the active compound per se after administration to a
subject.
[0010] Examples of well known methods of producing a prodrug of a given acting compound are known to those skilled
in the art and can be found e.g. in Krogsgaard- Larsen et al., Textbook of Drugdesign and Discovery, Taylor & Francis
(April 2002).  "Sodium channel blockers" or "sodium channel blocking compounds" encompass any chemicals that bind
selectively to a sodium channel and thereby deactivate the sodium channel. In particular they include chemicals which
bind to the SS1 or SS2 extracellular domains of an alpha subunit of a sodium channel. Sodium channel blocking com-
pounds that bind to the SS1 or SS2 subunit of a sodium channel, particularly tetrodotoxin and saxitoxin, are found to
possess similar pharmaceutical activity (US 6,407,088, hereby incorporated by reference).
[0011] Tetrodotoxin (alternatively in the context of this application abbreviated TTX), also known as Ti Qu Duo Xin, is
an alkaloid found in puffer fish (Tetradontiae). The chemical name is Octahydro-12-(Hydroxymethyl)-2-imino- 5, 9, 7,
10a-dimethano- 10aH-[1,3] dioxocino[6,5-d]pyrimidine-4,7,10,11,12-pentol with a molecular formula C11H17N3O8 and a
Molecular weight of 319.27. It is a potent non-protein neurotoxin and an indispensable tool for the study of neurobiology
and physiology. Tetrodotoxin (TTX) is a marine organic toxin which is mainly found in testicles, ovaries, eggs, livers,
spleens, eyeballs, and blood of puffer fish as well as in diverse animal species, including goby fish, newt, frogs and the
blue ringed octopus and even in marine alga. Several processes for producing TTX are known. Usually TTX is extracted
from marine organisms (e.g. JP 270719 Goto and Takahashi) but besides numerous others methods of synthesis are
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also described (and used for the preparation of tetrodotoxin in connection to this invention) in US 6,552,191, US6,478,966,
US 6,562,968 or 2002/0086997, all of which are included here by reference. Tetrodotoxin is a well known compound
described for example in WO02/22129 as systemically acting as analgesic. For one of the many descriptions of TTX it
is recommended turn to e.g. Tu, Anthony (Ed.) Handbook of Natural Toxins, Vol. 3: Marine Toxins and Venoms, 1988,
185-210 as well as Kao (1966), Pharmacol. Rev. 18:997 - 1049 and others.
[0012] The phrase "its (tetrodoxin’s) derivatives" according to this invention is defined - using the definition of US
6,030,974 (included here by reference) - as meaning amino perhydroquinazoline compounds having the molecular
formula C11H17N3O8. "Tetrodoxin’s derivatives" according to this invention encompasses compounds described in US
5,846,975 (included here by reference) as amino hydrogenated quinazolines and derivatives including the substances
set forth from column 3 line 40 to column 6 line 40. Specifically exemplified "derivatives of tetrodotoxin" according to this
invention are including but are not limited to anhydro-tetrodotoxin, tetrodaminotoxin, methoxytetrodotoxin, ethoxytetro-
dotoxin, deoxytetrodotoxin and tetrodonic acid, 6 epi-tetrodotoxin, 11- deoxytetrodotoxin as well as the hemilactal type
TTX derivatives (e.g. 4-epi-TTX, 6-epi-TTX, 11-deoxy-TTX, 4-epi-11-deoxy- TTX, TTX- 8-O-hemisuccinate, chiriquitoxin,
11-nor-TTX-6 (S)-ol, 11-nor-TTX-6 (R)-ol, 11-nor-TTX-6,6-diol, 11-oxo-TTX and TTX-11-carboxylic acid), the lactone
type TTX derivatives (e.g. 6-epi-TTX (lactone), 11-deoxy-TTX (lactone), 11-nor-TTX- 6 (S)-ol (lactone), 11-nor-TTX- 6
(R)-ol (lactone), 11-nor-TTX- 6,6- diol (lactone), 5-deoxy-TTX, 5,11-dideoxy-TTX, 4-epi-5,11-didroxy-TTX, 1-hydroxy-
5,11-dideoxy-TTX, 5,6,11-trideoxy-TTX and 4-epi-5,6,11-trideoxy-TTX) and the 4,9- anhydro type TTX analogs (e.g.
4,9-anhydro-TTX, 4,9-anhydro-6-epi-TTX, 4,9-anhydro-11-deoxy-TTX, 4,9-anhydro-TTX- 8-O-hemisuccinate, 4,9-an-
hydro-TTX-11-O-hemisuccinate). The typical derivatives of TTX possess only 1/8 to 1/40 of the toxicity of TTX in mice,
based upon bioassay in mice. It has been observed that these derivatives produce joint action, and do not interact
adversely. Examples of TTX derivatives include novel TTX derivatives isolated from various organisms, as well as those
that are partially or totally chemically synthesized (see e.g., Yotsu, M. et al. Agric. Biol. Chem., 53(3): 893-895 (1989) ).
[0013] "Derivatives and analogues of TTX", as referred to in the present invention, may include compounds having
the general formula I
wherein, R2 and R5 can be selected from the group consisting of H, OH, OAC, respectively;
R1 call be H, or an alkyl with C1-C4, OH, OR, OC(O) R’, NH2, NHR", NR"R"’, among them R can be an alkyl with C1-C6,
R’ can be an alkyl with C1-C3, and R", R"’ can be an alkyl with C1-C4, respectively;
R3 and R4 can be =O, or
when R3 is H, R4 can be selected from the group consisting of:
- ROH, and R is a branched or straight chain alkyl with C1-C7,
- CH(OH)NHOMe,
- NAP- gly,
- NAP- en,
- CH2NH2,
- CH2NHCH3,
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- AAG,
- NMAG, and
- ANT;
when R3 is OH or OC(O) R and R is an alkyl with C1-C3, R4 can be selected from the group consisting of:
- CHO,
- CH2-gly,
- CH2-β-Ala,
- CH2-Lys,
- CH2-en,
- CH2-NAP-Lys
- CH2-NAP-en,
- CH(OH)CH(NH2)COOH; and,
- NH(CH2)nCOOH,
- NH(CH2)nNH2; and
- NH(CH2)nCH (NH2)COOH,
wherein:
n=1-6.
en is ethylene; 
NAP is 4-triazo- 2- nitrobenzoic amide, indicated as formula (a);
AAG is 2-triazo-O- aminobenzoic amide, indicated as formular (b); 
NMAG is O-methylaminobenzoic amide, indicated as formula (c);
ANT is O-aminobenzoic amide, indicated as formula (d);
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[0014] Among them, three kinds of compounds with the general formula II, III, IV are alternative.
[0015] The amino hydrogenated quinazoline compounds and derivatives thereof are compounds having following
general formula II,
wherein: R1 can be selected from the group consisting of OH, an alkyl or a oxyalkyl with C1-C4, NH2, NHR", NR"R"’,
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among them R" and R"’ can be an alkyl with C1 -C4.
[0016] Among them, the more preferred compounds are:
Tetrodotoxin R1 =OH (1);
deoxytetrodotoxin R1=H (2);
[0017] The amino hydrogenated quiniazoline compounds and derivatives thereof are compounds having following
general formula III
wherein:
R3, R4 are=O, or
when R3 is H, R4 is selected from the group consisting of:
CH2OH,
CH(OH)NHOMe, 
- NAP- gly,
- NAP- en,
- CH2NH2,
- CH2NHCH3,
- AAG,
- NMAG, and
- ANT.
[0018] Among them, the more preferred compounds are:
AAG- degradation Tetrodotoxin R4=AAG (3);
NMAG-degradation Tetrodotoxin R4=NMAG (4);
ANT-degradation Tetrodotoxin R4=ANT (5); and,
degradation Tetrodotoxin R3, R4 is =O (6).
[0019] The amino hydrogenated quinazoline and their derivatives are compounds having following general formula IV, 
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wherein, R4 can be selected from the group consisting of:
- CHO,
- CH2-Gly,
- CH2-β-Ala,
- CH2-Lys,
- CH2-en,
- CH2-NAP-Lys
- CH2-NAP-en,
- -CH(OH)CH(NH2)COOH;
- NH(CH2)4CH (NH2)COOH;
- NHCH2COOH;
- NHCH2CH2COOH; and
- NHCH2CH2NH2.
[0020] Among them, the more preferred compounds are:
oxytetrodotoxin R4=CHO (7);
chiriquitoxin R4=CH(OH) CH(NH2)COOH (8);
and the compounds with the substituted groups of R4 : 
- NH(CH2)4 CH (NH2)COOH (9);
- NHCH2COOH (10);
- NHCH2CH2COOH (11); and,
- NHCH2 CH2 NH2 (12).
[0021] Saxitoxin (STX) and its pharmacologically acceptable salts are species of 2,6-diamino -4-((aminocarbonyl) oxy)
methyl-3a,4,8,9 -tetrahydro-1H, 10H- pyrrolo (1,2-c) purine -10,10- diol (3aS-(3a-a-a-4-a, 10aR*)). The molecular formula
of Saxitoxin is C10H17N7O4, it has a molecular weight of 299.3 and a general structure of:
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[0022] This, and its derivatives and its analogues may be used in accordance with the disclosure. Saxitoxin is readily
soluble in water and can be dispersed in aerosols. It is toxic by ingestion and by inhalation, with inhalation leading to
rapid respiratory collapse and death. Chemically, saxitoxin is stable, although it can be inactivated by treatment with
strong alkali. It is naturally- occurring, produced by bacteria that grow in other organisms, including the dinoflagellates
Gonyaulax catenella and G. tamarensis; which are consumed by the Alaskan butter clam Saxidomus giganteus and the
California sea mussel, Mytilus californianeus. The toxin can be isolated from S. giganteus or M. californianeus. The first
synthesis of STX was completed by Kishi and co- workers at Harvard in 1977 (J. Am. Chem. Soc. 1977, 99, 2818). A
second synthesis was carried out by Jacobi and his collaborators whilst at Wesleyan University, Connecticut (J. Am.
Chem. Soc. 1984, 106, 5594). A range of alternative methods for the synthesis and purification of saxitoxin will be
apparent to those skilled in the art. Analogues and derivatives of saxitoxin include but are not limited to neosaxitoxin
and anhydrosaxitoxin, any other biologically active variants of the above saxitoxin structure, and pharmaceutically ac-
ceptable salts thereof.
[0023] It will be appreciated that for the purposes set out herein, tetrodotoxin, saxitoxin, and their derivatives or
analogues or metabolite, can be optionally in the form of their racemate, pure stereoisomers, especially enantiomers or
diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable
ratio; in neutral form, in the form of an acid or base or in form of a salt, especially a physiologically acceptable salt, or
in form of a solvate, especially a hydrate.
[0024] In this application "about" means "approximately," and illustratively, the use of the term "about" indicates that
dosages slightly outside the cited ranges may also be effective and safe, and such dosages are also encompassed by
the scope of the present claims.
[0025] Compounds that are "administered together with TTX" or "in combination with TTX" may be administered as
part of the same composition, or may be administered separately, at the same or at separate times, in the same therapeutic
regimen.
[0026] In connection with this invention "neutral form" refers either to a non- ionic form or to a neutrally net charged
form, for example a Zwitter- lon at its isoelectric point.
[0027] The term "salt" according to this invention is to be understood as meaning any form of the active compound
according to the invention in which this compound assumes an ionic form or is charged and - if applicable - is also
coupled with a counter-ion (a cation or anion). By this are also to be understood complexes of the active compound with
other molecules and ions, in particular complexes which are complexed via ionic interactions. As preferred examples of
salts this includes the acetate, monotrifluoracetate, acetate ester salt, citrate, formate, picrate, hydrobromide, monohy-
drobromide, monohydrochloride or hydrochloride.
[0028] The term "physiologically acceptable salt" in the context of this invention is understood as meaning a "salt" (as
defined above) of at least one of the compounds according to the invention which are physiologically tolerated by humans
and/or mammals.
[0029] The term "solvate" according to this invention is to be understood as meaning any form of the active compound
according to the invention which has another molecule (most likely a polar solvent) attached to it via non-covalent
bonding. Examples of solvates include hydrates and alcoholates, e.g. methanolate.
[0030] The term "treatment" or "to treat" in the context of this specification means administration of a compound or
formulation according to the invention to prevent, ameliorate or eliminate one or more symptoms associated with preterm
labor and/or premature birth.
[0031] Furthermore, the terms "to treat" or "treatment" according to this invention include the treatment of symptoms
of preterm labor and/or premature birth, the prevention or the prophylaxis of the symptoms of preterm labor and/or
premature birth, the prevention or prophylaxis causing the symptoms of preterm labor and/or premature birth, as well
as the prevention or the prophylaxis of the consequences causing the symptoms.
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[0032] According to the various embodiments, the sodium channel blockers such as TTX or STX, their analogues/
derivatives or the pharmaceutical compositions comprising them, may be administered, in unit dosage form, intestinally,
enterally, parenterally or topically, orally, subcutaneously, intranasally, by inhalation, by oral absorption, intravenously,
intramuscularly, percutaneously, intraperitoneally, rectally, intravaginally, transdermally, sublingually, buccally, orally
transmucosally. Administrative dosage forms may include the following: tablets, capsules, dragees, lozenges, patches,
pastilles, gels, pastes, drops, aerosols, pills, powders, liquors, suspensions, emulsions, granules, ointments, creams,
suppositories, freeze-dried injections, injectable compositions, in food supplements, nutritional and food bars, syrups,
drinks, liquids, cordials etc, which could be regular preparation, delayed-released preparation, controlled-released prep-
aration and various micro- granule delivery system, in food supplements, nutritional and food bars, syrups, drinks, liquids,
cordials. In case of tablet, various carriers known in the art may be used, e.g. dilutent and resorbent such as starch,
dextrin, calcium sulfate, kaolin, microcrystalline cellulose, aluminium silicate, etc; wetting agent and adhesives such as
water, glycerin, polyethylene glycol, ethanol, propanol, starch mucilage, dextrin, syrup, honey, glucose solution, acacia,
gelatin, carboxymethylcellulose sodium, shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone, etc; dis-
integrating agent, such as dried starch, alginate, agar powder, laminaran, sodium bicarbonate and citric acid, calcium
carbonate, polyoxyethylene sorbitol aliphatic ester, lauryl sodium sulfate, methylcellulose, ethylcellulose, lactose, su-
crose, maltose, mannitol, fructose, various disaccharides and polysaccharides etc; disintegration inhibiting agent, such
as sucrose, tristearin, cacao butter, hydrogenated oil, etc; absorption accelerator, such as quaternary ammonium salt,
lauryl sodium sulfate, etc; lubricant, such as talc, silica, corn starch, stearate, boric acid, fluid wax, polyethylene, etc.
The tablet may be further formulated into coated tablet, e.g. sugar-coated tablet, film-coated tablet, enteric-coated tablet,
or double-layer tablet and multi- layer tablet. In the case of pill, various carriers known in the art may be used, e.g. dilutent
and resorbent, such as glucose, lactose, starch, cacao butter, hydrogenated vegetable oil, polyvinylpyrrolidone, kaolin,
talc, etc; adhesives, such as acacia, bassora gum, gelatin, ethanol, honey, liquid sugar, rice paste or flour paste, etc;
disintegrating agent, such as agar powder, dried starch, alginate, lauryl sodium sulfate, methylcellulose, ethylcellulose.
In case of suppository, various carriers known in the art may be used, e.g. polyethylene, lecithin, cacao butter, higher
alcohols, esters of higher alcohols, gelatin, semi-synthetic glyceride, etc. In the case of capsule, it may be prepared by
mixing said sodium channel blockers as active ingredient with the above mentioned carriers, followed by placing the
mixture into a hard gelatin capsule or soft capsule. Also, said sodium channel blockers may be applied in the following
dosage forms: microcapsules, suspension in an aqueous phase, hard capsule, or injection. In the case of injection, such
as liquor, emulsion, freeze- dried injection, and suspension, all the dilutents common in the art may be used, e.g. water,
ethanol, polyethylene glycol, propylene glycol, oxyethylated isostearyl alcohol, polyoxidated isostearyl alcohol, polyox-
yethylene sorbitol aliphatic ester, etc. In addition, in order to obtain isotonic injection, a suitable amount of sodium
chloride, glucose or glycerin may be added into the preparation, as well as regular cosolvent, buffer, pH adjusting agent,
etc. In addition, coloring agent, antiseptic, perfume, correctives, food sweetening agent or other materials may be added
to the pharmaceutical preparation if necessary.
[0033] In alternative embodiments the sodium channel blockers such as TTX or STX, their analogues/ derivatives may
be administered in a schedule of one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen,
fifteen, sixteen, seventeen, eighteen, nineteen, twenty or more doses per day, alone or in combination with other med-
ications, over range of time periods including but not limited to periods of one, two, three, four, five, six, seven, eight,
nine, ten, eleven, twelve, thirteen, fourteen, sixteen, eighteen, twenty, twenty four, thirty, or more days; or over a period
of one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, sixteen, eighteen, twenty,
twenty four, thirty, thirty six, forty eight, sixty, seventy two, eighty four or more months.
[0034] In particular embodiments the sodium channel blockers such as TTX or STX, their analogues/derivatives may
be a voltage-gated sodium channel blocker and may bind to a SS1 or SS2 α subunit of a sodium channel. The maximum
daily dose of sodium channel blocker may be up to about 10Pg, up to about 50Pg, up to about 100Pg, up to about
144Pg, up to about 150Pg, up to about 300Pg, up to about 500Pg, up to about 750Pg, up to about 1000Pg, up to about
1250Pg, up to about 1500Pg, up to about 1750Pg, up to about 2000Pg or more. In particular embodiments the sodium
channel blocker may be administered in an amount ranging between 5 and 4000 Pg/day, or in ranges between 10 and
2000Pg/day, 10 and 1000Pg a day, 10 and 750 Pg a day, 10 and 500 Pg a day, 10 and 400 Pg a day, 10 and 300 Pg
a day, 10 and 200 Pg a day, or 10 and 100 Pg/day.
[0035] In particular embodiments the daily applied dose may be from about 10 to about 160Pg, about 10 to about
140Pg, about 10 to about 120Pg, about 10 to about100 Pg, _about 10 to about 90Pg, about 10 to about 80Pg, about
10 to about 70Pg, about 10 to about 60 Pg, about 10 to about 50 Pg, about 10 to about 40Pg, about 10 to about 30Pg,
or 1 to 20Pg. In other embodiments the daily dosage of the sodium channel blocker may be about 0.1 to about 40Pg
per kilogram of body weight, about 1 to about 35Pg per kilogram of body weight, about 5 to about 30Pg per kilogram of
body weight, about 10 to about 30Pg per kilogram of body weight, about 15 to about 30Pg per kilogram of body weight,
about 10 to about 35Pg per kilogram of body weight, or about 20 to about 40Pg per kilogram of body weight. The unit
dose may be within a range of about 5Pg to about 2000Pg and may be about 5 to about10Pg, about 10 to about 15Pg,
about 15 to about 20Pg, about 20 to about 25Pg, about 25 to about 30 Pg, about 30 to about 40Pg, about 40Pg to about
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50Pg, about 50Pg to about 75Pg, about 75 to about100Pg, about 100 to about 150Pg, about 150 to about 200Pg, about
200 to about 250Pg, about 250 to about 500Pg, about 500 to about1000Pg, about 1000 to about 1500Pg or about 1500
to about 2000Pg or more than 2000Pg.
[0036] In some embodiments the effectiveness of a course of treatment of one, two, three, four, five or more doses
or one, two or three days may last for up to about five, ten, fifteen, twenty, twenty five or thirty. In some embodiments
dosing is only performed once every day or once every two, three, four, five, six, seven, eight, nine, ten, eleven, twelve,
thirteen, fourteen, sixteen, eighteen, twenty, twenty four, thirty or more days.
[0037] According to the present disclosure, the dosage of said sodium channel blocker such as TTX or STX, their
analogues/ derivatives, depends on a variety of factors, including the nature and severity of the diseases, the sex, age,
weight and individual reaction of the subject, the particular compound employed, the route and frequency of administration,
etc. Said sodium channel blockers such as TTX or STX, their analogues/derivatives or the pharmaceutical compositions
comprising them may be administered in single or divided dosage form, e.g. one to four doses per day. Those skilled
in the art will readily understand and implement the changes to the treatment methods exemplified herein that are
necessary or desirable to reflect varied therapeutic requirements.
[0038] A substance named as an "active ingredient" will have a purity of at least 97%. For example, a formulation said
to have "500 Pg of TTX as the active ingredient" may contain as much as 15 Pg of anhydrotetrodotoxin as an impurity.
On the other hand, a formulation said to have "500 Pg of TTX and 500 Pg of anhydrotetrodotoxin as active ingredients"
will contain at least 485 Pg of TTX and 485 Pg of anhydrotetrodotoxin, but may contain as much as 30 Pg of other
substances as impurities of the active ingredients. Of course, substances named as other components of a formulation
are not included when the purity of the active ingredient is considered.
[0039] An alternative embodiment of the present invention relates to the use of sodium channel blockers such as TTX
its analogues/derivatives, optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diaster-
eomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable mixing
ratio; in neutral form, in the form of an acid or base or in form of a salt, especially a physiologically acceptable salt, or
in form of a solvate, especially a hydrate for the production of a medicament for the treatment of preterm labor and/or
premature birth.
[0040] An alternative embodiment of the present invention relates to the use of sodium channel blockers such as STX
its analogues/derivatives, optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diaster-
eomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable mixing
ratio; in neutral form, in the form of an acid or base or in form of a salt, especially a physiologically acceptable salt, or
in form of a solvate, especially a hydrate for the production of a medicament for the treatment of preterm labor and/or
premature birth.
[0041] In an alternative embodiment of the invention the use according to the invention is restricted to tetrodotoxin as
the active ingredient. The TTX/STX is optionally provided in the form of its racemate, pure stereoisomers, especially
enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers,
preferably in a suitable ratio; in neutral form, in the form of an acid or base or in form of a salt, especially a physiologically
acceptable salt, or in form of a solvate, especially a hydrate.
[0042] In another alternative embodiment of the invention the use according to the invention is restricted to tetrodotoxin
as the active ingredient, preferably in any suitable ratio in neutral form or as a salt, especially a physiologically acceptable
salt.
[0043] In another alternative embodiment of the invention the use according to the invention is restricted to saxitoxin
as the active ingredient, preferably in any suitable ratio in neutral form or as a salt, especially a physiologically acceptable
salt.
[0044] More prefereably, tetrodotoxin is in neutral form or as a salt, especially a physiologically acceptable salt.
[0045] Preferably, the derivatives/analogues of tetrodotoxin comprise tetrodotoxin, anhydrotetrodotoxin, tetrodamino-
toxin, methoxytetrodotoxin, ethoxytetrodotoxin, deoxytetrodotoxin, epi-tetrodotoxin and tetrodonic acid.
[0046] In another alternative embodiment of the invention tetrodotoxin, any of its derivatives and/or one of its analogues
is used as the active ingredient in an amount between 10 Pg/day and 4 mg/day.
[0047] In another alternative embodiment of the invention tetrodotoxin, its derivative or its analogue is isolated from
a biological source, preferably from fish, especially puffer fish.
[0048] In another alternative embodiment of the invention tetrodotoxin, its derivative or its analogue is synthetic.
[0049] In another alternative embodiment of the invention is the use of tetrodotoxin, one of its analogues/derivatives,
for the production of a medicament for the treatment of preterm labor.
[0050] In an alternative embodiment of the invention is the use of tetrodotoxin, one of its analogues/derivatives, for
the production of a medicament for the treatment of premature birth.
[0051] Yet, in another alternative embodiment of the present invention tetrodotoxin reduces the number of uterus
contractions to ≤12 contractions per hour, more preferably ≤8 contractions per hour, most preferably ≤4 contractions
per hour.
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[0052] Another alternative embodiment of the present invention refers to a method for the treatment of premature
birth, said method comprising administering to a mammal TTX and/or one of its analogues or derivatives.
[0053] Another alternative embodiment of the present invention refers to a method for the treatment of preterm labor,
said method comprising administering to a mammal TTX and/or one of its analogues or derivatives.
[0054] Another alternative embodiment of the present invention refers to a kit to administer TTX and/or one of its
analogues or derivatives, said kit comprising said TTX and/or one of its analogues and/or derivatives channel blocker
and instructions to use it to treat premature birth.
[0055] Another alternative embodiment of the present invention refers to a kit to administer TTX and/or one of its
analogues or derivatives, said kit comprising said TTX and/or one of its analogues and/or derivatives channel blocker
and instructions to use it to treat preterm labor.
[0056] Another alternative embodiment of the present invention refers to a kit to administer STX and/or one of its
analogues or derivatives, said kit comprising said TTX and/or one of its analogues and/or derivatives channel blocker
and instructions to use it to treat premature birth.
[0057] Another alternative embodiment of the present invention refers to a kit to administer STX and/or one of its
analogues or derivatives, said kit comprising said TTX and/or one of its analogues and/or derivatives channel blocker
and instructions to use it to treat preterm labor.
[0058] Another alternative embodiment of the present invention refers to a kit comprising TTX and/or one of its ana-
logues or derivatives, optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers
or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers; preferably in any suitable ratio; in
neutral form, in the form of an acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of
a solvate, especially a hydrate.
[0059] The examples and figures in the following section describing pharmacological trials are merely illustrative and
the invention cannot be considered in any way as being restricted to these applications.
Examples
Pharmacological Experiments
Materials and Methods
Animals.
[0060] Three-month- old virgin female Wistar rats purchased from Charles River Laboratories were housed with a light:
dark cycle of 12h: 12h and provided with food and water ad libitum. Animals in an undetermined stage of the ovarian
cycle, or in the estrous stage of the ovarian cycle (as determined by microscopic examination of a vaginal smear), were
killed humanely and the uterine horns rapidly removed, dissected free of adhering fat and mesentery and opened
longitudinally.
Organ bath studies.
[0061] Functional studies were performed essentially as described by (Pinto et al. (Endocrinology 140 2526-2532).
Strips of uterine longitudinal smooth muscle similar in weight and length were prepared and mounted in tissue baths
containing 4 ml of Krebs solution of the following composition (mM): NaCl 118; KCI 4.7; CaCl2 1.9 or 1.1; MgSO4 1.1;
KH2PO4 1.18; NaHCO3 25 and glucose 11. Some experiments were carried out in physiological solution with a low
concentration of glucose (1 mM) or in a Ca2+-free medium.
Veratridine-induced uterine contractions
[0062] Uterine strips were suspended under an initial tension of 5 mN, gassed with 95% O2/ 5% CO2 and maintained
at 37°C. Mechanical responses were recorded isometrically by means of force- displacement transducers (Grass FT-
03). Preparations were allowed to equilibrate for a 60 min period before addition of single or cumulative concentrations
of the selective Na+ channel activators veratridine (1-100 PM); brevetoxin-B (0.1 nM-0.1 PM); grayanotoxin (10-60 PM)
or aconitine (1-300 PM). Only one compound was tested on each tissue. At the end of the experiment, preparations
were washed repeatedly and induced to contract at least two times by addition of KCl (40 mM) and metacholine (0.1
mM) at 30 min intervals. We analyzed the effect of different inhibitors on uterine contractions elicited by Nav activators.
Single or cumulative concentrations of an inhibitor or its vehicle (time-matched paired controls) were added to uterine
strips exposed to a Nav activator for different time periods. The effect of inhibitors was also assessed in uterine strips
mounted in parallel and precontracted by 40 mM KCI.
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Spontaneous or electrically-induced uterine contractions
[0063] In other experiments, we studied the effect of several inhibitors on rhythmic contractions developed spontane-
ously by the uterine strips or induced electrically. Field electrical stimulation was delivered throPgh platinum electrodes
incorporated into the tissue holders. Trains of pulses (2 ms, 25 V, 30 Hz) were applied for 5 s every 100 s, using a Grass
SI 1 stimulator connected to a multiplier (Stimu-Splitter II, Med- Lab). One inhibitor (0.1 PM TTX, 1 PM atropine or 1 PM
prazosin) or its solvent was assayed in time-matched paired uterine strips after 40-min suspension in the organ baths.
Simultaneous measurement of contractile force and [Ca2+]i.
[0064] Small strips of myometrium (approximately 5 mm in length, 1 mm in width, 0.1 mm in thickness) were excised
from the longitudinal smooth muscle layer under binocular control. The muscle strips were treated with the acetoxymethyl
ester form of Fura- 2 (Fura- 2/AM, 20 PM, Molecular Probes, Invitrogen, Eugene, OR, USA) for 2-4 hours at room tem-
perature. The noncytotoxic detergent pluronic acid (0.02 %, Molecular Probes) was added to increase the solubility of
the Ca2+-sensitive fluorophore. Following the Fura-2/AM loading, the myometrial fiber was rinsed and placed in the
quartz cuvette of a fluorimeter designed to measure changes in the fluorescence signals of FURA-2 simultaneously with
force development in biological tissues (SLM Aminco-Bowman, Series 2, Microbeam, Barcelona, Spain) The tissue was
incubated at 37°C in oxygenated (100% O2) physiological salt solution of the following composition (mM): NaCl 154;
KCI 5.6; CaCl2 2; MgSO4 1.2; glucose 11 and HEPES 11, adjusted to pH 7.4. The strip was attached to a Grass FT-03
force displacement transducer and suspended under an initial tension of 5 mN. To measure [Ca2+]i, the myometrial fiber
was alternatively illuminated with two excitations wavelengths (340 nm and 380 nm) from a xenon lamp coupled with
two monochromators. The emitted fluorescent light at the two excitation wavelengths (F340 and F380) was measured
by a photomultiplier throPgh a 510- nm filter. After subtracting the background signal, obtained by adding 5 mM MnCl2
at the end of the experiment, the fluorescence ratio (F340/F380) was used as an indicator of [Ca2+]i, essentially as
described by Taggart et al., J. Physiol. 499, 485-496. Both contractile force and [Ca2+]i. were recorded by using data
acquisition system and data recording software provided by the manufacturer.
[0065] All values are expressed as the mean  SEM and, except where otherwise stated, n represents the number
of rats used. Statistical analyses of data from functional studies were performed by one- way analysis of variance (ANOVA)
followed by Dunnett’s or Tukey’s multiple comparison test and Student’s unpaired t- test to compare the means of two
groups (GRAPHPAD PRISM 4.0, California, USA). Statistical significance was accepted when P < 0.05.
Results
1) Functional responses
[0066] In 1.9 mM Ca2+-containing solution, uterine preparations obtained from non-pregnant rats in an undetermined
stage of the ovarian cycle exhibited rhythmic contractions that disappeared during the first 90 min of the experiment in
80% of tissues. In a medium containing 1.1 mM Ca2+, the spontaneous contractions ceased during the first 90 min of
the experiment in 99% of tissues. After cessation of initial activity, we analyzed the mechanical effects produced by
cumulative addition of veratridine (1-100 PM), brevetoxin-B (0.1 nM- 0.1 PM), grayanotoxin (10-60 PM) or aconitine
(1-300 PM). The four Na+ channel agonists induced rhythmic contractions of irregular amplitude and frequency which
appeared at concentrations ≥10 PM for veratridine (n=25), ≥10 nM for brevetoxin- B (n=6), ≥100 PM for aconitine (n=5)
and ≥20 PM for grayanotoxin (n=4). The time-course and the characteristics of the contractile response elicited by each
compound were similar in strips isolated from the medial, ovarian or cervical regions of the uterine horn. The maximal
response, measured during a 60 min application, was reached with 60 PM veratridine, 30 nM brevetoxin, 100 PM
aconitine and 30 PM grayanotoxin and was, for each compound, virtually identical in uterine strips incubated in 1.9 or
1.1 mM Ca2+-containing solution (Fig. 1). In all cases, addition of TTX (0.1 PM, n=75 uterine strips from 25 different
rats) caused the immediate abolition of the rhythmic contractions (see Fig. 2). They were also inhibited by nifedipine (1
PM, n=12 uterine strips from 3 rats) and did not appear in uterine strips incubated in a Ca2+-free physiological solution
containing 1 mM EGTA (n=12 uterine strips from 3 different rats). Subsequent experiments were carried out in uterine
strips isolated from any region of the uterine horn and obtained from rats that were spontaneously in the estrous stage
of the ovarian cycle. The physiological solution contained 1.1 mM Ca2+ and veratridine was used as the Nav agonist.
2) Effects of TTX on Veratridine- induced uterine contractions
[0067]
a) Addition of TTX (0.1 PM) caused the immediate abolition of the rhythmic contractions (see Fig. 2).
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b) Additionally, we analysed the effects of the specific Nav1.4 blocker P-conotoxin GIIIB (Cruz et al., J. Biol. Chem.
260, 9280-9288), the class IC antiarrhythmic drug flecainide that blocks Nav1.5 and Nav1.4 (Tamargo et al., 1998;
Desaphy et al., 2004) and the purported blocker of Nav1.8 vinpocetine (Zhou et al., JPET, 306, 498-504). In uterine
strips exposed for 90 min (late response) to 60 PM veratridine, application of cumulative concentrations of P-
conotoxin GIIIB (0.1 nM-10 PM), flecainide (1 nM-30 PM) or vinpocetine (1 nM- 30 PM) did not modify the veratridine-
induced rhythmic contractions (data not shown). Similar results were obtained when these blockers were applied
in preparations exposed to veratridine for 40 min. Cumulative addition of TTX (0.3 nM-1 PM) caused a concentration-
dependent inhibition of the early and late contraction to veratridine with -log IC50 values of 8.20  0.19 (n=15) and
8.02  0.17 (n=11 uterine strips from 7 animals), respectively. Application of cumulative concentrations of TTX (0.3
nM-10 PM) had no effect on KCl- induced uterine contraction (data not shown).
3) Characterization of veratridine-induced uterine contractions.
[0068] The uterine contraction to veratridine (60 PM) could be clearly divided in two different phases. The initial
response was observed during the first 50-60 min of exposure and consisted of transient contractions of irregular am-
plitude and frequency (Figs. 2 and 3). In the continuous presence of veratridine, a second, late response appeared that
consisted of rhythmic contractions of very regular frequency (Figs. 2 and 3a). The amplitude of these late contractions,
and hence the area under the force- time curve, which gives a measure of the whole contractile response, slightly
increased during aproximately 180 min, i.e., during the first 240 min of contact of the preparation with veratridine (Figs.
2, 3b and 4). From this moment, the contractile response remained very regular and well maintained for at least 12 h
after addition of veratridine (24 uterine strips from 12 different animals, Fig. 4). The response was identical and had a
similar duration time in a physiological solution containing only 1 mM glucose (n = 4, not shown).
4) Effects of TTX on spontaneous or electrically- induced uterine contractions
[0069] We also analyzed the effect of TTX (0.1 PM), atropine (1 PM) and prazosin (1 PM) on spontaneous contractions
developed by the uterine strips after 40- min in physiological solution containing 1.9 mM Ca2+. TTX caused a decrease
of the contractile area (to 66.7  4.0% of the contraction during 10 min prior to the addition of TTX, n = 27) or had no
effect (117.0  7.2% of the previous contraction, n = 13). The TTX solvent decreased the spontaneous contraction (to
78.50  2.71%, n = 20) or had no effect (128.5  14.8%, n = 20). The inhibitory effect of TTX was significantly different
from the inhibitory effect of the solvent (P <0.05, Student’s t- test for unpaired data). Atropine caused a great inhibition
(to 26.7  2.2% of the previous contractile area, n = 20) while its solvent had no effect (90.3  8.5%, n = 20). Atropine
abolished or almost abolished spontaneous uterine contractions when added 10- or 20-min after uterine stretch. Prazosin
or its solvent did not affect spontaneous activity (107.6  9.1%, n = 10 and 128.7  13.5%, n = 10, respectively). 
TTX caused a decrease of the contractile area of electrically-induced uterine contractions (to 69.2  3.0% of the con-
traction during 10 min prior to the addition of TTX, n = 54 uterine strips from 40 different rats). Atropine decreased the
response (to 30.3  8.1, n = 10) and prazosin was without effect (92.3  4.0% of the previous contraction, n = 7)
5) Effects of TTX on contractile force and [Ca2+]i.
[0070] In isolated myometrial fibers loaded with Fura- 2, veratridine caused rhythmic contractions accompanied by
transient increases in [Ca2+]i. This response was observed in a half of the strips assayed (n= 10 of 21 uterine strips,
obtained from 12 different rats). The mean amplitude during a 10- min period (8.48  1.20 mN) and the frequency of
contractions (0.75  0.09 min-1) were similar to values observed in uterine strips. Both the contractile force and the
[Ca2+]i transients were abolished by addition of 0.1 PM TTX (Fig. 6).
Figures
[0071] Figure 1: Contractile responses elicited by veratridine (60 PM), brevetoxin- B (30 nM), aconitine (100
PM) and grayanotoxin (30 PM) in uterine strips from non- pregnant rats incubated in physiological solution
containing 1.9 or 1.1 mM Ca2+. Responses were measured as the amplitude of the rhythmic contractions during a 60
min contact period and expressed as a percentage of the maximal amplitude of the control response to KCI. Bars
represent means with SEM shown by vertical lines. Numbers in parentheses indicate number of experiments in different
animals.
[0072] Figure 2: Original trace showing the typical contractile response induced by veratridine (60 PM) and
its inhibition by tetrodotoxin (TTX, 0.1 PM) in isolated uterine strips from non- pregnant rats. Reference contractions
produced by KCI (40 mM) and metacholine (MCh, 0.1 mM) are also shown. w, washing.
[0073] Figure 3: Frequency (A, contractions/min) and amplitude (B, as percentage of the KCl maximal re-
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sponse) of the rhythmic contractions induced by veratridine (60 PM) in isolated uterine strips from non- pregnant
rats. Responses were measured during successive intervals of 10 min, for a 180 min contact period. Bars represent
means of experiments in 18 different rats, with SEM shown by vertical lines. a,b,c,dSignificant differences from contractile
amplitude at 10, 20, 30 and 40 min, respectively, P<0.05, one- way analysis of variance.
[0074] Figure 4: Contractile response induced by veratridine (60 PM) in isolated uterine strips from non-
pregnant rats. Responses were measured as the area under the force-time curve during successive intervals of 1 hour,
for a 12 hours contact period and were expressed as a percentage of the area to KCI during a 60 min period. Bars
represent means of experiments in 24 uterine strips from 12 different rats, with SEM shown by vertical lines. a,b,cSignificant
differences from contractile area at 1, 2 and 3 hours, respectively, P<0.05, one-way analysis of variance.
[0075] Figure 5: Effect of mecamylamine (1 PM), suramin (100 PM), yohimbine (1 PM), atropine (Atrop, 1 PM),
prazosin (Praz, 1 PM) and propanolol (Prop, 1 PM) on the veratridine- induced uterine contraction. Responses
were measured as the area under the force-time curve during a 10 min period of contact of the inhibitor or its solvent
(control tissues) with the preparation and expressed as a percentage of the response to veratridine (area) during the 10
min previous to the addition of the inhibitor or solvent. Bars represent means of experiments in 5 to 8 different rats, with
SEM shown by vertical lines. Significant differences from control tissues: *P< 0.05, one-way analysis of variance.
[0076] Figure 6: Simultaneous recording of the effect of veratridine (60 PM) in contractile force (top) and [Ca2+]i
(Fura-2 ratio, bottom) and its inhibition by tetrodotoxin (TTX, 0.1 PM) in myometrial strips from non- pregnant rats.
Examples of Pharmaceutical Compositions
Orally administerable formulations
Example 1: Capsule Formulations
[0077]
Example of a formulation (A) for a Capsule
Tetrodotoxin (TTX) (powdered material) 0.03 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
Lactose 98.47 mg
Total 100 mg
Example of a formulation (B) for a Capsule
Tetrodotoxin (TTX) (powdered material) 0.15 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
Lactose 98.35 mg
Total 100 mg
Example of a formulation (C) for a Capsule
Tetrodotoxin (TTX) (powdered material) 0.3 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
Lactose 98.2 mg
Total 100 mg
Example of a formulation (D) for a Capsule
Tetrodotoxin (TTX) (powdered material) 0.9 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
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Example 2: Tablet Formulations
[0078]
(continued)
Example of a formulation (D) for a Capsule
Lactose 97.6 mg
Total 100 mg
Example of a formulation (E) for a Capsule
Tetrodotoxin (TTX) (powdered material) 0.25 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
Lactose 98.25 mg
Total 100 mg
Example of a formulation (F) for a Capsule
Tetrodotoxin (TTX) (powdered material) 0.5 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
Lactose 98.0 mg
Total 100 mg
Example of a formulation (G) for a Capsule
Tetrodotoxin (TTX) (powdered material) 1.0 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
Lactose 97.5 mg
Total 100 mg
Example of a formulation (H) for a Capsule
Tetrodotoxin (TTX) (powdered material) 1.5 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
Lactose 97.0 mg
Total 100 mg
Example of a formulation (A) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.03 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
Sodium croscarmelose 5.0 mg
Lactose 93.47 mg
Total 100 mg
Example of a formulation (B) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.15 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
Sodium croscarmelose 5.0 mg
Lactose 93.35 mg
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(continued)
Example of a formulation (B) for a tablet
Total 100 mg
Example of a formulation (C) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.3 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
Sodium croscarmelose 5.0 mg
Lactose 93.2 mg
Total 100 mg
Example of a formulation (D) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.9 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
Sodium croscarmelose 5.0 mg
Lactose 92.6 mg
Total 100 mg
Example of a formulation (E) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.25 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
Sodium croscarmelose 5.0 mg
Lactose 93.25 mg
Total 100 mg
Example of a formulation (F) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.5 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
Sodium croscarmelose 5.0 mg
Lactose 93.0 mg
Total 100 mg
Example of a formulation (G) for a tablet
Tetrodotoxin (TTX) (powdered material) 1.0 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
Sodium croscarmelose 5.0 mg
Lactose 92.5 mg
Total 100 mg
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Example 3: Additional Tablet Formulations
Example of a formulation (A) for a tablet (humid Granulation)
[0079]
(continued)
Example of a formulation (H) for a tablet
Tetrodotoxin (TTX) (powdered material) 1.5 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
Sodium croscarmelose 5.0 mg
Lactose 92.0 mg
Total 100 mg
Tetrodotoxin (TTX) (powdered material) 0.03 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
POVIDONE K-30 5.0 mg
Sodium carboxymethylstarch 5.0 mg
Microcrystalline cellulose 20 mg
Lactose 68.47 mg
Total 100 mg
Example of a formulation (B) for a tablet (humid Granulation)
Tetrodotoxin (TTX) (powdered material) 0.15 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
POVIDONE K-30 5.0 mg
Sodium carboxymethylstarch 5.0 mg
Microcrystalline cellulose 20 mg
Lactose 68.35 mg
Total 100 mg
Example of a formulation (C) for a tablet (humid Granulation)
Tetrodotoxin (TTX) (powdered material) 0.3 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
POVIDONE K-30 5.0 mg
Sodium carboxymethylstarch 5.0 mg
Microcrystalline cellulose 20 mg
Lactose 68.2 mg
Total 100 mg
Example of a formulation (D) for a tablet (humid Granulation)
Tetrodotoxin (TTX) (powdered material) 0.9 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
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[0080]
(continued)
Example of a formulation (D) for a tablet (humid Granulation)
POVIDONE K-30 5.0 mg
Sodium carboxymethylstarch 5.0 mg
Microcrystalline cellulose 20 mg
Lactose 67.6 mg
Total 100 mg
Example of a formulation (E) for a tablet (humid Granulation)
Tetrodotoxin (TTX) (powdered material) 0.25 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
POVIDONE K-30 5.0 mg
Sodium carboxymethylstarch 5.0 mg
Microcrystalline cellulose 20 mg
Lactose 68.25 mg
Total 100 mg
Example of a formulation (F) for a tablet (humid Granulation)
Tetrodotoxin (TTX) (powdered material) 0.5 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
POVIDONE K-30 5.0 mg
Sodium carboxymethylstarch 5.0 mg
Microcrystalline cellulose 20 mg
Lactose 68.0 mg
Total 100 mg
Example of a formulation (G) for a tablet (humid Granulation)
Tetrodotoxin (TTX) (powdered material) 1.0 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
POVIDONE K-30 5.0 mg
Sodium carboxymethylstarch 5.0 mg
Microcrystalline cellulose 20 mg
Lactose 67.5 mg
Total 100 mg
Example of a formulation (H) for a tablet (humid Granulation)
Tetrodotoxin (TTX) (powdered material) 1.5 mg
Colloidal silicon dioxide 0.5 mg
Magnesium stearate 1.0 mg
POVIDONE K-30 5.0 mg
Sodium carboxymethylstarch 5.0 mg
Microcrystalline cellulose 20 mg
Lactose 67.0 mg
Total 100 mg
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Example of a formulation (A) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.03 mg
Sodium croscarmelose (AC-DI-SOL) 40 mg
Colloidal silica dioxide (AEROSYL 200) 8 mg
Magnesium stearate, NF 16 mg
POVIDONE K-30 40 mg
Microcrystalline cellulose (AVICEL PH-102) 346 mg
Lactose monohydrate (FARMATOSE 200M) 365.97mg
Total 800 mg
Example of a formulation (B) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.06 mg
Sodium croscarmelose (AC-DI-SOL) 40 mg
Colloidal silica dioxide (AEROSYL 200) 8 mg
Magnesium stearate, NF 16 mg
POVIDONE K-30 40 mg
Microcrystalline cellulose (AVICEL PH-102) 346 mg
Lactose monohydrate (FARMATOSE 200M) 365.94mg
Total 800 mg
Example of a formulation (C) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.12 mg
Sodium croscarmelose (AC-DI-SOL) 40 mg
Colloidal silica dioxide (AEROSYL 200) 8 mg
Magnesium stearate, NF 16 mg
POVIDONE K-30 40 mg
Microcrystalline cellulose (Avicel PH- 102) 346 mg
Lactose monohydrate (FARMATOSE 200M) 365.88mg
Total 800 mg
Example of a formulation (D) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.18 mg
Sodium croscarmelose (AC-DI-SOL) 40 mg
Colloidal silica dioxide (AEROSYL 200) 8 mg
Magnesium stearate, NF 16 mg
POVIDONE K-30 40 mg
Microcrystalline cellulose (Avicel PH- 102) 346 mg
Lactose monohydrate (FARMATOSE 200M) 365.82mg
Total 800 mg
Example of a formulation (E) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.3 mg
Sodium croscarmelose (AC-DI-SOL) 40 mg
Colloidal silica dioxide (AEROSYL 200) 8 mg
Magnesium stearate, NF 16 mg
POVIDONE K-30 40 mg
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(continued)
Example of a formulation (E) for a tablet
Microcrystalline cellulose (Avicel PH- 102) 346 mg
Lactose monohydrate (FARMATOSE 200M) 365.7 mg
Total 800 mg
Example of a formulation (F) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.9 mg
Sodium croscarmelose (AC-DI-SOL) 40 mg
Colloidal silica dioxide (AEROSYL 200) 8 mg
Magnesium stearate, NF 16 mg
POVIDONE K-30 40 mg
Microcrystalline cellulose (Avicel PH- 102) 346 mg
Lactose monohydrate (FARMATOSE 200M) 365.1 mg
Total 800 mg
Example of a formulation (G) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.25 mg
Sodium croscarmelose (AC-DI-SOL) 40 mg
Colloidal silica dioxide (AEROSYL 200) 8 mg
Magnesium stearate, NF 16 mg
POVIDONE K-30 40 mg
Microcrystalline cellulose (Avicel PH- 102) 346 mg
Lactose monohydrate (FARMATOSE 200M) 365.75mg
Total 800 mg
Example of a formulation (H) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.5 mg
Sodium croscarmelose (AC-DI-SOL) 40 mg
Colloidal silica dioxide (AEROSYL 200) 8 mg
Magnesium stearate, NF 16 mg
POVIDONE K-30 40 mg
Microcrystalline cellulose (Avicel PH- 102) 346 mg
Lactose monohydrate (FARMATOSE 200M) 365.5 mg
Total 800 mg
Example of a formulation (I) for a tablet
Tetrodotoxin (TTX) (powdered material) 1.0 mg
Sodium croscarmelose (AC-DI-SOL) 40 mg
Colloidal silica dioxide (AEROSYL 200) 8 mg
Magnesium stearate, NF 16 mg
POVIDONE K-30 40 mg
Microcrystalline cellulose (Avicel PH- 102) 346 mg
Lactose monohydrate (FARMATOSE 200M) 365.0 mg
Total 800 mg
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Example 5: Additional Tablet Formulations
[0081]
(continued)
Example of a formulation (J) for a tablet
Tetrodotoxin (TTX) (powdered material) 1.5 mg
Sodium croscarmelose (AC-DI-SOL) 40 mg
Colloidal silica dioxide (AEROSYL 200) 8 mg
Magnesium stearate, NF 16 mg
POVIDONE K-30 40 mg
Microcrystalline cellulose (Avicel PH- 102) 346 mg
Lactose monohydrate (FARMATOSE 200M) 364.5 mg
Total 800 mg
Example of an alternative formulation (A) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.03 mg
Sodium croscarmelose (AC- DI-SOL) 35 mg
Colloidal silica dioxide (AEROSYL 200) 3 mg
Sodium stearate 12 mg
Polyethylene glycol 8000 30 mg
Microcrystalline cellulose (Avicel PH-102) 75 mg
Lactose monohydrate (FARMATOSE 200M) 420.97mg
OPADRY II ® 24 mg
Total 600 mg
Example of an alternative formulation (B) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.15 mg
Sodium croscarmelose (AC- DI-SOL) 35 mg
Colloidal silica dioxide (AEROSYL 200) 3 mg
Sodium stearate 12 mg
Polyethylene glycol 8000 30 mg
Microcrystalline cellulose (Avicel PH-102) 75 mg
Lactose monohydrate (FARMATOSE 200M) 420.85mg
OPADRY II ® 24 mg
Total 600 mg
Example of an alternative formulation (C) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.3 mg
Sodium croscarmelose (AC- DI-SOL) 35 mg
Colloidal silica dioxide (AEROSYL 200) 3 mg
Sodium stearate 12 mg
Polyethylene glycol 8000 30 mg
Microcrystalline cellulose (Avicel PH-102) 75 mg
Lactose monohydrate (FARMATOSE 200M) 420.7 mg
OPADRY II® 24 mg
Total 600 mg
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(continued)
Example of an alternative formulation (D) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.9 mg
Sodium croscarmelose (AC- DI-SOL) 35 mg
Colloidal silica dioxide (AEROSYL 200) 3 mg
Sodium stearate 12 mg
Polyethylene glycol 8000 30 mg
Microcrystalline cellulose (Avicel PH-102) 75 mg
Lactose monohydrate (FARMATOSE 200M) 420.1 mg
OPADRY II ® 24 mg
Total 600 mg
Example of an alternative formulation (E) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.25 mg
Sodium croscarmelose (AC- DI-SOL) 35 mg
Colloidal silica dioxide (AEROSYL 200) 3 mg
Sodium stearate 12 mg
Polyethylene glycol 8000 30 mg
Microcrystalline cellulose (Avicel PH-102) 75 mg
Lactose monohydrate (FARMATOSE 200M) 420.75mg
OPADRY II ® 24 mg
Total 600 mg
Example of an alternative formulation (F) for a tablet
Tetrodotoxin (TTX) (powdered material) 0.5 mg
Sodium croscarmelose (AC- DI-SOL) 35 mg
Colloidal silica dioxide (AEROSYL 200) 3 mg
Sodium stearate 12 mg
Polyethylene glycol 8000 30 mg
Microcrystalline cellulose (Avicel PH-102) 75 mg
Lactose monohydrate (FARMATOSE 200M) 420.5 mg
OPADRY II ® 24 mg
Total 600 mg
Example of an alternative formulation (G) for a tablet
Tetrodotoxin (TTX) (powdered material) 1.0 mg
Sodium croscarmelose (AC- DI-SOL) 35 mg
Colloidal silica dioxide (AEROSYL 200) 3 mg
Sodium stearate 12 mg
Polyethylene glycol 8000 30 mg
Microcrystalline cellulose (Avicel PH-102) 75 mg
Lactose monohydrate (FARMATOSE 200M) 420.0 mg
OPADRY II ® 24 mg
Total 600 mg
Example of an alternative formulation (H) for a tablet
Tetrodotoxin (TTX) (powdered material) 1.5 mg
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Example 6: Additional Capsule Formulations
[0082]
(continued)
Example of an alternative formulation (H) for a tablet
Sodium croscarmelose (AC- DI-SOL) 35 mg
Colloidal silica dioxide (AEROSYL 200) 3 mg
Sodium stearate 12 mg
Polyethylene glycol 8000 30 mg
Microcrystalline cellulose (Avicel PH-102) 75 mg
Lactose monohydrate (FARMATOSE 200M) 419.5mg
OPADRY II® 24 mg
Total 600 mg
Example of an alternative formulation (A) of a capsule
Tetrodotoxin 0.03 mg
Colloidal silica dioxide 0.8 mg
Magnesium stearate 2.4 mg
Lactose 476.77 mg
Total 480 mg
Example of an alternative formulation (B) of a capsule
Tetrodotoxin 0.15 mg
Colloidal silica dioxide 0.8 mg
Magnesium stearate 2.4 mg
Lactose 476.65 mg
Total 480 mg
Example of an alternative formulation (C) of a capsule
Tetrodotoxin 0.3 mg
Colloidal silica dioxide 0.8 mg
Magnesium stearate 2.4 mg
Lactose 476.5 mg
Total 480 mg
Example of an alternative formulation (D) of a capsule
Tetrodotoxin 0.9 mg
Colloidal silica dioxide 0.8 mg
Magnesium stearate 2.4 mg
Lactose 475.9 mg
Total 480 mg
Example of an alternative formulation (E) of a capsule
Tetrodotoxin 0.25 mg
Colloidal silica dioxide 0.8 mg
Magnesium stearate 2.4 mg
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EXAMPLE 7: Outwardly Solid Formulations
Encapsulated outwardly solid formulation (A)
[0083]
0.5 ml of this prepared solution were encapsulated in suitable consumable capsules and stored.
Encapsulated outwardly solid formulation (B):
[0084]
0.5 ml of this prepared solution were encapsulated in suitable consumable capsules and stored.
(continued)
Example of an alternative formulation (E) of a capsule
Lactose 476.55 mg
Total 480 mg
Example of an alternative formulation (F) of a capsule
Tetrodotoxin 0.5 mg
Colloidal silica dioxide 0.8 mg
Magnesium stearate 2.4 mg
Lactose 476.3 mg
Total 480 mg
Example of an alternative formulation (G) of a capsule
Tetrodotoxin 1.0 mg
Colloidal silica dioxide 0.8 mg
Magnesium stearate 2.4 mg
Lactose 475.8 mg
Total 480 mg
Example of an alternative formulation (H) of a capsule
Tetrodotoxin 1.5 mg
Colloidal silica dioxide 0.8 mg
Magnesium stearate 2.4 mg
Lactose 475.3 mg
Total 480 mg
Tetrodotoxin 60 mg
0.5% dilute acetic acid 1 ml
Acetic Acid-acetate buffer solution (pH=3.5 50 ml (5% of the total volume of the prepared pharmaceutical solution)
Water, sterile, add to 1000 ml
Tetrodotoxin 300 mg
0.5% dilute acetic acid 1 ml
Acetic Acid-acetate buffer solution (pH=3.5 50 ml (5% of the total volume of the prepared pharmaceutical solution)
Water, sterile, add to 1000 ml
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Encapsulated outwardly solid formulation (C)
[0085]
0.5 ml of this prepared solution were encapsulated in suitable consumable capsules and stored.
Encapsulated outwardly solid formulation (D)
[0086]
0.5 ml of this prepared solution were encapsulated in suitable consumable capsules and stored.
Encapsulated outwardly solid formulation (E)
[0087]
0.5 ml of this prepared solution were encapsulated in suitable consumable capsules and stored.
Encapsulated outwardly solid formulation (F)
[0088]
0.5 ml of this prepared solution were encapsulated in suitable consumable capsules and stored.
Encapsulated outwardly solid formulation (G)
[0089]
Tetrodotoxin 600 mg
0.5% dilute acetic acid 1 ml
Acetic Acid-acetate buffer solution (pH=3.5 50 ml (5% of the total volume of the prepared pharmaceutical solution)
Water, sterile, add to 1000 ml
Tetrodotoxin 1800 mg
0.5% dilute acetic acid 1 ml
Acetic Acid-acetate buffer solution (pH=3.5 50 ml (5% of the total volume of the prepared pharmaceutical solution)
Water, sterile, add to 1000 ml
Tetrodotoxin 500 mg
0.5% dilute acetic acid 1 ml
Acetic Acid-acetate buffer solution (pH=3.5 50 ml (5% of the total volume of the prepared pharmaceutical solution)
Water, sterile, add to 1000 ml
Tetrodotoxin 1000 mg
0.5% dilute acetic acid 1 ml
Acetic Acid-acetate buffer solution (pH=3.5 50 ml (5% of the total volume of the prepared pharmaceutical solution)
Water, sterile, add to 1000 ml
Tetrodotoxin 2000 mg
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0.5 ml of this prepared solution were encapsulated in suitable consumable capsules and stored.
Encapsulated outwardly solid formulation (H)
[0090]
0.5 ml of this prepared solution were encapsulated in suitable consumable capsules and stored.
EXAMPLE 8:
Example of a further alternative formulation of a tablet ready to be processed into an enteric- coated formulation
[0091]
EXAMPLE 9:
[0092]
EXAMPLE 10:
Example of another form of tablet ready to be processed into a coated controlled- release formulation
[0093]
(continued)
0.5% dilute acetic acid 1 ml
Acetic Acid-acetate buffer solution (pH=3.5 50 ml (5% of the total volume of the prepared pharmaceutical solution)
Water, sterile, add to 1000 ml
Tetrodotoxin 3000 mg
0.5% dilute acetic acid 1 ml
Acetic Acid-acetate buffer solution (pH=3.5 50 ml (5% of the total volume of the prepared pharmaceutical solution)
Water, sterile, add to 1000 ml
Tetrodotoxin 0.5 mg
Dibasic Calcium Phosphate USP 46.8 mg
Avicel PH 101 50.0 mg
NATROSOL 250 HHX 1.0 mg
CAB- O- SIL M5 0.5 mg
Magnesium Stearate NF 1.0 mg
Yellow Lake F D & C No 6 0.2 mg
Purified Water USP (evaporates during the process)
Total 100 mg
Example of an enteric- coated version of example 8
Tablet according to Example 8 100 mg
Acryl- Eze yellow coating suspension House Std 40.0 mg
Tetrodotoxin 0.5 mg
Dibasic Calcium Phosphate USP 40.0 mg
Avicel PH 101 46.8 mg
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EXAMPLE 11:
Example of a coated controlled-release version of example 10
[0094]
EXAMPLE 12:
Example of a further alternative formulation of a tablet ready to be processed into a coated formulation
[0095]
EXAMPLE 13:
Example of a coated version of example 12
[0096]
EXAMPLE 14:
Example of a further alternative formulation of a tablet ready to be processed into an enteric- coated formulation
[0097]
(continued)
NATROSOL 250 HHX 10.0 mg
CAB- O- SIL M5 0.5 mg
Magnesium Stearate NF 2.0 mg
Blue F D & C No1 0.2 mg
Purified Water USP (evaporates during the process)
Total 100 mg
Tablet according to Example 10 100 mg
SURETERIC Blue suspension House Std 20.0 mg
90/10 SURELEASE / OPADRY clear suspension 30.0 mg
Tetrodotoxin 0.5 mg
Dibasic Calcium Phosphate USP 46.0 mg
Avicel PH 101 50.0 mg
AC-DI-SOL 2.0 mg
CAB- O- SIL M5 0.5 mg
Magnesium Stearate NF 1.0 mg
Purified Water USP (evaporates during the process)
Total 100 mg
Tablet according to Example 12 100 mg
OPADRY II coating suspension House Std 20.0 mg
Tetrodotoxin 1.0 mg
Dibasic Calcium Phosphate USP 46.3 mg
Avicel PH 101 50.0 mg
NATROSOL 250 HHX 1.0 mg
CAB- O- SIL M5 0.5 mg
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EXAMPLE 15:
Example of an enteric-coated version of example 14
[0098]
EXAMPLE 16:
Example of another form of tablet ready to be processed into a coated controlled- release formulation
[0099]
EXAMPLE 17:
Example of a coated controlled-release version of example 16
[0100]
EXAMPLE 18:
Example of a further alternative formulation of a tablet ready to be processed into a coated formulation
[0101]
(continued)
Magnesium Stearate NF 1.0 mg
Yellow Lake F D & C No 6 0.2 mg
Purified Water USP (evaporates during the process)
Total 100 mg
Tablet according to Example 14 100 mg
Acryl-Eze yellow coating suspension House Std 40.0 mg
Tetrodotoxin 1.0 mg
Dibasic Calcium Phosphate USP 40.0 mg
Avicel PH 101 46.3 mg
NATROSOL 250 HHX 10.0 mg
CAB- O- SIL M5 0.5 mg
Magnesium Stearate NF 2.0 mg
Blue F D & C No1 0.2 mg
Purified Water USP (evaporates during the process)
Total 100 mg
Tablet according to Example 16 100 mg
SURETERIC Blue suspension House Std 20.0 mg
90/10 SURELEASE / OPADRY clear suspension 30.0 mg
Tetrodotoxin 1.0 mg
Dibasic Calcium Phosphate USP 45.5 mg
Avicel PH 101 50.0 mg
AC-DI-SOL 2.0 mg
CAB- O- SIL M5 0.5 mg
Magnesium Stearate NF 1.0 mg
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EXAMPLE 19:
Example of a coated version of example 18
[0102]
With the guidance provided herein, once the required parameters of a composition or method are known, those skilled
in the art will be readily able to determine the amounts and proportions of active components and other components
required to manufacture a required dosage form, manufacture a kit or composition, or use the methods and compositions
disclosed. The foregoing embodiments have been described in detail by way of illustration and example for purposes
of clarity and understanding. As is readily apparent to one skilled in the art, the foregoing are only some of the methods
and compositions that illustrate the possible embodiments. It will be apparent to those of ordinary skill in the art that a
range of equivalents, variations, changes, modifications and alterations may be applied to the compositions and methods
described herein without departing from the true spirit, concept and scope of the invention.
Claims
1. Use of tetrodotoxin, one of its analogues/ derivatives, for the production of a medicament for the treatment of preterm
labor and/or premature birth.
2. Use, according to claim1, characterized in that tetrodotoxin is optionally in the form of its racemate, pure stereoi-
somers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers
or diastereomers, in any suitable ratio; in neutral form, in the form of an acid or base or in form of a salt, especially
a physiologically acceptable salt, or in form of a solvate, especially a hydrate.
3. Use according to any of claims 1 or 2 characterized in that the use restricted to tetrodotoxin in neutral form or as
a salt, especially a physiologically acceptable salt.
4. Use according to any of claims 1 to 3, characterized in that tetrodotoxin, at least one of its derivatives and/or one
of its analogues is used in an amount between 10 Pg/day and 4 mg/day.
5. Use according to any of claims 1 to 4, characterized in that tetrodotoxin, its derivatives or its analogues, are isolated
from a biological source, preferably from fish, especially puffer fish.
6. Use according to any or claims 1 to 4, characterized in that tetrodotoxin, its derivatives or its analogues, are synthetic.
7. Use according to any of claims 1 to 6, characterized in that tetrodotoxin reduces the number of uterus contractions
to ≤12 contractions per hour, more preferably ≤8 contractions per hour, most preferably ≤4 contractions per hour.
8. Use according to any of claims 1 to 7, characterized in that the use is restricted to preterm labor.
9. Use according to any of claims 1 to 7, characterized in that the use is restricted to premature birth.
(continued)
Purified Water USP (evaporates during the process)
Total 100 mg
Tablet according to Example 18 100 mg
OPADRY II coating suspension House Std 20.0 mg
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